Please login to the form below

Not currently logged in
Email:
Password:

early access

This page shows the latest early access news and features for those working in and with pharma, biotech and healthcare.

Merus makes case for bispecific antibody in specific cancer gene fusion

Merus makes case for bispecific antibody in specific cancer gene fusion

Could become a potential treatment for hard-to-treat cancers. Merus, a Dutch biotech developing full-length bispecific antibodies, has presented early clinical data of its lead candidate in cancers with ... The experimental drug, named MCLA-128, was

Latest news

More from news
Approximately 72 fully matching, plus 153 partially matching documents found.

Latest Intelligence

  • Assessing the risks in annuity pricing models Assessing the risks in annuity pricing models

    that as more of these therapies advance toward commercialisation, stakeholders are increasingly working to develop innovative payment strategies to support market access and address concerns about budget impact, including a strong ... They may need to

  • New models of NHS care – new models of pharma response? New models of NHS care – new models of pharma response?

    For this new environment, we need people who understand a patient pathway and how to access it. ... Instead of being highly trained sales people, they need to be highly efficient facilitators, helping HCPs to get patients early access to the right

  • Mylan sees the UK paving the way for an insulin game changer Mylan sees the UK paving the way for an insulin game changer

    increased. patient access. “They need to recognise that this is the opportunity of the century and they should seize it.”. ... We are looking at a hybrid solution that offers favourable pricing and increased access for the patients.

  • Accelerating diagnosis in rare disease Accelerating diagnosis in rare disease

    Diagnosis of rare disease is challenging; physicians may only see a handful of cases in their career and information surrounding them is often lacking or difficult to access. ... CROs and trial design • Early access and regulation • Value

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Ambitious strategy. “Companies need to set an ambitious strategy for pricing and market access early on,” Barham continues. ... No system is perfect,” Barham concludes. “But there is scope for improvements in all countries to try to reach a

More from intelligence
Approximately 5 fully matching, plus 36 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics